ConductScience.org, home

Paper41807809

A year in pharmacology: new drugs approved by the US food and drug administration in 2025.

Kayki-Mutlu G and 3 others. Naunyn Schmiedebergs Arch Pharmacol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A year in pharmacology: new drugs approved by the US food and drug administration in 2025. Papers, record 41807809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41807809

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A year in pharmacology: new drugs approved by the US food and drug administration in 2025.
PubMed
Journal
Naunyn Schmiedebergs Arch Pharmacol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kayki-Mutlu GGizem
2Aksoyalp ZSZinnet Sevval
3Wojnowski LLeszek
4Michel MCMartin C

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug ApprovalMajor topic
United States
Humans
United States Food and Drug Administration
Animals

References137

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136253825Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.Orphanet J Rare Dis2022https://conductscience.org/library/papers/36253825PubMed
236951997A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.Naunyn Schmiedebergs Arch Pharmacol2023https://conductscience.org/library/papers/36951997PubMed
340880034Linvoseltamab: First Approval.Drugs2025https://conductscience.org/library/papers/40880034PubMed
437959392A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence.J Clin Med2023https://conductscience.org/library/papers/37959392PubMed
540570869Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.Lancet2025https://conductscience.org/library/papers/40570869PubMed
640673861Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis.J Allergy Clin Immunol Pract2025https://conductscience.org/library/papers/40673861PubMed
740540142Revakinagene Taroretcel: First Approval.Mol Diagn Ther2025https://conductscience.org/library/papers/40540142PubMed
838879802Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.J Clin Oncol2024https://conductscience.org/library/papers/38879802PubMed
940261472Garadacimab: First Approval.Drugs2025https://conductscience.org/library/papers/40261472PubMed
1041594098In Vitro Activity of Zoliflodacin Against Neisseria gonorrhoeae Isolates from Shanghai, China (2020-2023).Antibiotics (Basel)2026https://conductscience.org/library/papers/41594098PubMed
1124914142Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.Blood2014https://conductscience.org/library/papers/24914142PubMed
1240779124Nipocalimab: First Approval.Drugs2025https://conductscience.org/library/papers/40779124PubMed
1341222831Taletrectinib: First Approval.Drugs2026https://conductscience.org/library/papers/41222831PubMed
1440864501FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.Clin Cancer Res2025https://conductscience.org/library/papers/40864501PubMed
1537932009Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.Ann Rheum Dis2024https://conductscience.org/library/papers/37932009PubMed
1640222822Rilzabrutinib for the Treatment of Immune Thrombocytopenia.Eur J Haematol2025https://conductscience.org/library/papers/40222822PubMed
1741212379Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations.Invest New Drugs2025https://conductscience.org/library/papers/41212379PubMed
1839947256Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?Pharmacol Ther2025https://conductscience.org/library/papers/39947256PubMed
1940924012
Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).
Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40924012PubMed
2037639462Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.Eur Heart J2023https://conductscience.org/library/papers/37639462PubMed

See all 137 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41807809

GET https://conductscience.org/api/papers/v1/41807809/references?page=2